# A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

> **NCT05392127** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** SHR0302 Tablets
- **DRUG:** Midazolam Maleate Tablets
- **DRUG:** Warfarin Sodium Tablets
- **DRUG:** Omeprazole Enteric Capsules
- **DRUG:** Vitamin K1 Tablets
- **DRUG:** Repaglinide Tablets

## Key facts

- **NCT ID:** NCT05392127
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-15
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-08-18
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05392127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05392127, "A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05392127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*